Market Overview - US stock indices closed higher, with the S&P 500 and Nasdaq reaching their highest closing levels in over four months. The Dow Jones rose by 1.19%, Nasdaq by 1.43%, and S&P by 1.11% [1] - The VIX index fell by 11.85% to 17.48, indicating reduced market volatility [1] - The US dollar index decreased by 0.42% to 97.97, while the yield on the 10-year Treasury bond dropped by 1.173% to 4.297% [1] Industry & Stocks - Most sectors in the S&P 500 saw gains, with semiconductor and technology sectors leading the way, rising by 3.79% and 1.8% respectively. Energy and consumer staples were the only sectors to decline, down by 1.3% and 0.09% [1] - Chinese concept stocks mostly rose, with notable increases in TSMC (up 4.65%), Alibaba (up 3.47%), and Pinduoduo (up 5.11%) [1] - Major tech stocks also saw gains, with Nvidia rising by 2.59% and Amazon by 2.06%. However, Apple fell by 0.6% and Tesla by 2.35% [2] Company Highlights - FedEx reported fourth-quarter revenue of $22.2 billion, exceeding analyst expectations of $21.75 billion. However, the company did not provide full-year guidance due to global demand uncertainty [12] - Meta Platforms achieved a market share of 50.8% in the AR/VR headset market, leading a strong rebound with a year-on-year growth of 18.1% [13] - UBS raised its valuation for Tesla's Robotaxi business to $350 billion, assuming successful execution and regulation, which is an increase from a previous valuation of $225 billion [16] Regulatory & Economic Insights - The International Bank for Settlements stated that stablecoins fail to meet the three main tests of currency due to lack of central bank support and insufficient protection against illegal use [5] - The Federal Reserve's Chairman Powell indicated that the path for future interest rates could vary significantly based on economic conditions, with no immediate need for rate cuts [10][11]

Financial Performance - In Q1 2025, the company reported revenue of 880 million yuan, a year-on-year decline of 1.6%, primarily due to the divestment of its real estate business [1] - The net profit attributable to shareholders was 50.712 million yuan, down 14.1% year-on-year, influenced by reduced income, decreased profits from associated companies, and increased R&D expenses [1] - The non-recurring net profit was 46.990 million yuan, a year-on-year decrease of 9.7% [1] Profitability Metrics - The gross margin improved to 51.3%, an increase of 0.5 percentage points year-on-year [1] - The net profit margin was 7.2%, down 1.0 percentage point year-on-year [1] - The selling expense ratio decreased to 35.5%, down 0.8 percentage points year-on-year, while the management expense ratio increased to 4.7%, up 0.6 percentage points year-on-year [1] Cosmetics Segment - The cosmetics segment generated revenue of 530 million yuan, a year-on-year decline of 2.6%, with a gross margin of 61.1% [2] - The Yilian brand achieved revenue of 250 million yuan, a year-on-year increase of 25%, while the Ai'er Doctor brand saw revenue decline by 18.4% to 240 million yuan [2] - The segment focused on R&D and technological innovation, with 12 new patents authorized and 47 new products launched [2] Pharmaceutical and Raw Materials Segment - The pharmaceutical business achieved revenue of 110 million yuan, remaining stable year-on-year, with a gross margin of 54.8% [3] - The raw materials and derivatives segment generated revenue of 90 million yuan, a year-on-year increase of 2.4%, with a gross margin of 29.7% [3] - The company launched 8 new health food products and received international patent authorization for sodium hyaluronate quaternary ammonium salt [3] Future Outlook - The company maintains its profit forecast, expecting net profits attributable to shareholders to be 330 million, 370 million, and 420 million yuan for 2025-2027, corresponding to PE ratios of 23, 20, and 18 times [3] - The company anticipates significant growth signals in 2025, driven by consumer spending and the expansion of its skincare and sub-brands [3]

Investment Rating - The report maintains a "Buy" rating for the company [2] Core Views - The company reported Q1 2025 earnings that met market expectations, with total revenue of 876 million yuan, a year-on-year decline of 1.6%, primarily due to the divestment of its real estate business. The net profit attributable to shareholders was 50.71 million yuan, down 14.1% year-on-year, influenced by reduced revenue, decreased profits from associates, and increased R&D expenses [7][10] - The gross margin improved to 51.3%, up 0.5 percentage points year-on-year, while the net profit margin was 7.2%, down 1.0 percentage points. The sales expense ratio decreased to 35.5%, down 0.8 percentage points year-on-year [7][12] - The cosmetics segment showed resilience, with revenue of 530 million yuan, a year-on-year decline of 2.6%, and a gross margin of 61.1%. The Yilian brand achieved revenue of 250 million yuan, a 25% increase year-on-year, while the Aierbos brand saw a revenue decline of 18.4% [7] - The pharmaceutical and raw materials segments remained stable, with pharmaceutical revenue at 110 million yuan, maintaining year-on-year levels, and a gross margin of 54.8%. The raw materials segment achieved revenue of 90 million yuan, a 2.4% increase year-on-year [7] - The company aims to leverage its R&D advantages to build a comprehensive health industry chain across cosmetics, raw materials, and pharmaceuticals. The report maintains profit forecasts for 2025-2027, expecting net profits of 330 million, 370 million, and 420 million yuan, corresponding to P/E ratios of 23, 20, and 18 times [7] Financial Data and Profit Forecast - Total revenue for 2025 is projected at 4,009 million yuan, with a year-on-year growth rate of 0.7%. The net profit attributable to shareholders is expected to be 329 million yuan, reflecting a growth rate of 35.1% [6] - The gross margin is anticipated to improve to 57.8% in 2025, with a return on equity (ROE) of 7.5% [6]